Back to Journals » Infection and Drug Resistance » Volume 13

How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections

Authors Taati Moghadam M, Amirmozafari N, Shariati A, Hallajzadeh M, Mirkalantari S, Khoshbayan A, Masjedian Jazi F

Received 11 October 2019

Accepted for publication 23 December 2019

Published 7 January 2020 Volume 2020:13 Pages 45—61

DOI https://doi.org/10.2147/IDR.S234353

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Eric Nulens


Majid Taati Moghadam,1 Nour Amirmozafari,1 Aref Shariati,1,2 Masoumeh Hallajzadeh,1 Shiva Mirkalantari,1 Amin Khoshbayan,1,2 Faramarz Masjedian Jazi1,3

1Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; 2Student Research Committee, Iran University of Medical Sciences, Tehran, Iran; 3Microbial Biotechnology Research Center, Iran University of Medical Science, Tehran, Iran

Correspondence: Faramarz Masjedian Jazi
Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Tel +989123905926
Email Masjedian.f@iums.ac.ir

Abstract: Nowadays the most important problem in the treatment of bacterial infections is the appearance of MDR (multidrug-resistant), XDR (extensively drug-resistant) and PDR (pan drug-resistant) bacteria and the scarce prospects of producing new antibiotics. There is renewed interest in revisiting the use of bacteriophage to treat bacterial infections. The practice of phage therapy, the application of phages to treat bacterial infections, has been around for approximately a century. Phage therapy relies on using lytic bacteriophages and purified phage lytic proteins for treatment and lysis of bacteria at the site of infection. Current research indicates that phage therapy has the potential to be used as an alternative to antibiotic treatments. It is noteworthy that, whether phages are used on their own or combined with antibiotics, phages are still a promising agent to replace antibiotics. So, this review focuses on an understanding of challenges of MDR, XDR, and PDR bacteria and phages mechanism for treating bacterial infections and the most recent studies on potential phages, cocktails of phages, and enzymes of lytic phages in fighting these resistant bacteria.

Keywords: bacteriophage, drug resistant, MDR, XDR, PDR

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]